Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06397885

Prospective on Market Patient-reported Outcomes for Milli

To assess the effectiveness of the Milli device in achieving vaginal intercourse

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

The Milli Vaginal Dilator is a patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion.

This study is intended to provide data in support of the Milli Vaginal Dilator as a commercially available, over-the-counter medical device.

The Milli has been granted marketing authorization by the FDA under premarket notification K220035 for the following Indications for Use statement:

The Milli Vaginal Dilator is a tool indicated for controlled dilation of the vagina. It can be used for dilation for an examination (by your doctor), in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex.

.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is a female at birth aged ≥18 years of age
  • Subject is able to read and understand the approved, informed consent form (ICF)
  • Subject meets vaginismus and related painful sex/GPPPD criteria as defined in the DSM-5, as confirmed by having one or more of the following for greater than 6 months:
  • Pelvic pain
  • Vaginal pain
  • Pain with vaginal intercourse
  • Pain with vaginal penetration
  • Fear or anxiety about vaginal or pelvic pain with vaginal penetration
  • The inability to achieve vaginal penetration
  • Subject currently has a sexual partner with a functional penis
  • Subject is currently seeking vaginal penetration to achieve sexual intercourse
  • Subject is currently unable to tolerate vaginal penetration to achieve sexual intercourse (Score of ≤1 on PEQ Question #1)
  • Subject purchased Milli vaginal dilator
  • Subject is not contraindicated for Milli vaginal dilator use
  • Subject is able and willing to comply with study protocol

Exclusion criteria

  • Subject has previously participated in any studies by the company in the past 12 months or has used Milli prior to enrollment
  • Subject is pregnant
  • Subject has an active pelvic infection (vagina or vulva)
  • Subject has open wounds in the tissue inside or surrounding the vagina
  • Subject has an untreated major mental health disorder (e.g., affective disorder, psychosis, PTSD)
  • Subject has prior history of gender-confirming surgery, vaginal reconstruction surgery, pelvic radiation, and/or vaginal procedures that result in extensive scarring (with the exception of hysterectomy procedures)
  • Subject or subject's partner experiences other conditions preventing intercourse (e.g., erectile dysfunction, lack of libido)

Treatment and study plan

Milli Vaginal Dilator

Device

Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion

Primary outcomes

  1. Penetration Efficiency Questionnaire

    Time frame: 6 months

    Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as measured by the Penetration Efficiency Questionnaire (Score of ≥2 on PEQ Question #1) at six months

Secondary outcomes

  1. Penetration Efficiency Questionnaire

    Time frame: 3 months

    Ability to achieve full vaginal penetration with the penis of the partner (intercourse) as

  2. Penetration Efficiency Questionnaire

    Time frame: 3 months, 6 months

    Improvement in ability to achieve vaginal penetration (intercourse and non-intercourse) as measured by a change in baseline in the overall score on the Penetration Efficiency Questionnaire at 3 and 6 months.

  3. Female Sexual Function Index (FSFI)

    Time frame: 3 months, 6 months

    Improvement in self-reported sexual function as reported on a change in baseline in the Female Sexual Function Index (FSFI) total score at 3 and 6 months.

  4. Numerical Rating Scale

    Time frame: 3 months, 6 months

    Improvement in self-reported pain intensity with intercourse as reported as a change in baseline on a numeric rating scale (NRS) (0= no pain, 10 = worst pain imaginable) at 3 and 6 months

Sponsors and collaborators

Lead sponsor

Materna Medical

Industry

Registry information

Acronym: POMPOM

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 3, 2024
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.